BSE Live
Apr 06, 16:01Prev. Close
150.60
Open Price
150.00
Bid Price (Qty.)
145.20 (11)
Offer Price (Qty.)
147.70 (183)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Makers Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 4.78 | 1.21 | 4.97 | -1.16 | 7.03 | |
| Diluted EPS (Rs.) | 4.78 | 1.21 | 4.97 | -1.16 | 7.03 | |
| Cash EPS (Rs.) | 7.89 | 3.19 | 7.02 | 0.91 | 8.46 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 50.08 | 46.58 | 45.37 | 40.40 | 41.57 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 50.08 | 46.58 | 45.37 | 40.40 | 41.57 | |
| Dividend / Share(Rs.) | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | |
| Revenue from Operations/Share (Rs.) | 132.02 | 139.06 | 125.17 | 126.93 | 109.91 | |
| PBDIT/Share (Rs.) | 9.34 | 5.27 | 11.06 | 3.28 | 14.04 | |
| PBIT/Share (Rs.) | 6.24 | 3.29 | 9.01 | 1.21 | 12.61 | |
| PBT/Share (Rs.) | 6.91 | 2.42 | 7.09 | -1.31 | 10.44 | |
| Net Profit/Share (Rs.) | 4.78 | 1.21 | 4.97 | -1.16 | 7.03 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 7.07 | 3.78 | 8.83 | 2.58 | 12.77 | |
| PBIT Margin (%) | 4.72 | 2.36 | 7.19 | 0.95 | 11.46 | |
| PBT Margin (%) | 5.23 | 1.73 | 5.66 | -1.03 | 9.49 | |
| Net Profit Margin (%) | 3.62 | 0.87 | 3.96 | -0.91 | 6.39 | |
| Return on Networth / Equity (%) | 9.55 | 2.60 | 10.94 | -2.87 | 16.90 | |
| Return on Capital Employed (%) | 8.04 | 2.14 | 10.01 | -2.58 | 14.99 | |
| Return on Assets (%) | 6.01 | 1.45 | 6.30 | -1.50 | 9.00 | |
| Total Debt/Equity (X) | 0.03 | 0.09 | 0.20 | 0.40 | 0.54 | |
| Asset Turnover Ratio (%) | 166.03 | 166.68 | 158.82 | 163.85 | 140.87 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.22 | 1.78 | 1.50 | 1.19 | 1.11 | |
| Quick Ratio (X) | 1.28 | 1.03 | 0.78 | 0.59 | 0.59 | |
| Inventory Turnover Ratio (X) | 7.02 | 6.89 | 6.02 | 6.49 | 6.85 | |
| Dividend Payout Ratio (NP) (%) | 20.90 | 0.00 | 0.00 | 0.00 | 14.23 | |
| Dividend Payout Ratio (CP) (%) | 12.67 | 0.00 | 0.00 | 0.00 | 11.82 | |
| Earnings Retention Ratio (%) | 79.10 | 100.00 | 100.00 | 0.00 | 85.77 | |
| Cash Earnings Retention Ratio (%) | 87.33 | 100.00 | 100.00 | 0.00 | 88.18 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 28.73 | 9.73 | 12.95 | 17.77 | 25.92 | |
| EV/Net Operating Revenue (X) | 0.44 | 0.14 | 0.21 | 0.28 | 0.48 | |
| EV/EBITDA (X) | 6.25 | 3.76 | 2.38 | 11.03 | 3.76 | |
| MarketCap/Net Operating Revenue (X) | 0.43 | 0.11 | 0.15 | 0.16 | 0.29 | |
| Retention Ratios (%) | 79.09 | 100.00 | 100.00 | 0.00 | 85.76 | |
| Price/BV (X) | 1.14 | 0.34 | 0.40 | 0.51 | 0.77 | |
| Price/Net Operating Revenue | 0.43 | 0.11 | 0.15 | 0.16 | 0.29 | |
| Earnings Yield | 0.08 | 0.08 | 0.27 | -0.06 | 0.22 |
20.02.2026
Makers Labs Consolidated December 2025 Net Sales at Rs 35.67 crore, up 28.81% Y-o-Y
19.02.2026
Makers Labs Standalone December 2025 Net Sales at Rs 12.70 crore, up 34.43% Y-o-Y
14.11.2025
Makers Labs Consolidated September 2025 Net Sales at Rs 34.17 crore, up 15.58% Y-o-Y
12.11.2025
Makers Labs Standalone September 2025 Net Sales at Rs 12.64 crore, up 9.89% Y-o-Y
20.02.2026
Makers Labs Consolidated December 2025 Net Sales at Rs 35.67 crore, up 28.81% Y-o-Y
19.02.2026
Makers Labs Standalone December 2025 Net Sales at Rs 12.70 crore, up 34.43% Y-o-Y
14.11.2025
Makers Labs Consolidated September 2025 Net Sales at Rs 34.17 crore, up 15.58% Y-o-Y
12.11.2025
Makers Labs Standalone September 2025 Net Sales at Rs 12.64 crore, up 9.89% Y-o-Y
06.04.2026
06.04.2026
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth